New guidelines for recurrent ovarian cancer


New ASCO Guidelines for the Post-PARP Era in Recurrent Ovarian Cancer

Study Reference: Journal of Clinical Oncology (2026) 

The Bottom Line

There are new guidelines for managing recurrent ovarian cancer, prompted by the widespread adoption of front-line PARP inhibitor (PARPi) maintenance, which has fundamentally altered how recurrences behave. Ovarian cancer following PARPi therapy often regains DNA repair capability, making traditional platinum-based cytotoxic chemotherapies far less effective, with consequent limited expectation of survival. The guidelines now suggest testing for Folate Receptor Alpha (FR-alpha) to identify the one-third of patients who would benefit from combination Antibody/drug therapy (ADC). The guidelines emphasise clinical trial enrolment alongside holistic care discussions, including early integration of palliative care.

Key Points

  • Realistic Prognostic Framing & Palliative Care: The guidelines emphasise introducing supportive care early to manage symptoms, align treatment intensity with patient preferences, and maintain quality of life.

  • The Post-PARP Resistance Problem: Prior exposure to PARP inhibitors changes tumour biology, reducing the reliability of classic platinum-free survival.

  • Biomarker Testing is Essential: Testing for FR-alpha is now standard practice at recurrence to guide second-line ADC options.

  • Trial Enrolment: Because standard chemotherapy shows reduced efficacy after PARPi progression, other measures such as joining a clinical trial may be suggested.

What This Means for Ovarian Cancer Support Nurses

Clinical ChallengePractical Action for Support Lines
Normalising Holistic CareRefocus conversations around holistic and palliative support right at recurrence. Callers often hear "palliative" and panic, equating it solely with end-of-life care. Reframing this early helps patients see it as an essential layer of symptom management and emotional support alongside active treatment.
Explaining Chemo ResistanceReassure callers who feel confused when their oncologist skips a traditional platinum re-challenge like carboplatin. Explain that tumors breaking through PARP inhibitors frequently fix their own DNA repair mechanisms, rendering standard cytotoxic chemo much less effective.
Navigating FR-alpha TestingHelp callers understand the role of biomarker testing. Since roughly one in three patients will test positive for FR-alpha, getting this biopsy/tissue check done allows access to targeted antibody-drug conjugates like mirvetuximab soravtansine.
Encouraging Trial DiscussionsGive callers practical wording to take to their next appointment. Encouraging them to ask, "Given my biomarker profile, are there any open clinical trials we should consider?" gives them a clear path forward when conventional options narrow.

Tags: #ASCOGuidelines #RecurrentOvarianCancer #PARPInhibitors #Mirvetuximab #ADC #FolateReceptorAlpha #PalliativeCare #SupportNursing

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more

Recurrent OC subtypes

Image
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer https://tinyurl.com/47mcxyde Women unfortunate enough to develop a recurrence of ovarian cancer show a range of responses to repeat chemo. This study looks at the immune response to the cancer and the survival outcomes. About half of these women show the presence of tumour infiltrating lymphocytes, (TIL),  suggesting an active cell-mediated immune response. This is associated with better survival. Most of those women also display defective DNA repair with Homologous Recombination Deficiency (HRD). The immune response is stimulated by increased antigen s such as PD-1 , which suggest that immunotherapy with immune checkpoint inhibitors could be of benefit. However, in practice this has not seen to be true. T o understand why this is the case the authors reviewed the immune status of abut 600 patients with ovarian cancer using digital pathology. They subdivided the immune r...
Read more